GLP-1RAs are known to delay gastric emptying a condition in which the stomach empties slower than normal potentially leading to the presence of residual gastric content (RGC) in appropriately fasted patients
124,125,126 The design concept of these multi-agonists is to simultaneously regulate multiple key metabolic pathways to achieve more effective control over blood sugar, body weight, and overall metabolic health
Exenatide, when combined with metformin, has been shown to significantly suppress the proliferation of breast cancer cells [104]
Given these benefits, GLP-1s are a powerful tool in the fight against obesity and metabolic dysfunction and have revolutionized treatments
For patients without insurance, the cost of drugs like Wegovy or Ozempic can reach $1,000 per month
Leech, C